Piroxicam encapsulated in liposomes: Characterization and in vivo evaluation of topical anti-inflammatory effect

Drug Development and Industrial Pharmacy

Volumn 25, Issue 12, 1999, Pages 1235-1239

  Canto, G S ^a   Dalmora, S L ^a   Oliveira, A G ^b  

^a Centro de Ciencias da Saude   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

In vivo evaluation; Liposomes; Piroxicam; Topical application

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; HYDROXYETHYLCELLULOSE; LIPOSOME; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; PIROXICAM; POLYCARBONATE;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ENCAPSULATION; NONHUMAN; PELLET EXTRUSION; RAT; TOPICAL DRUG ADMINISTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG CARRIERS; GRANULOMA; INFLAMMATION; LIPOSOMES; PIROXICAM; RATS; RATS, WISTAR;

EID: 0032762654     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-100102293     Document Type: Article

References (32)

1. D.D. Lasic and D. Papahadjoupoulos, Medical Application of Liposomes, Elsevier, New York, 1998.
2. M. Mezei and V. Gulasekharam, Life Sci., 26, 1473-1477 (1980).
3. A. Gursoy, J. Akhuga, and L. J. Eroglu, Pharm. Pharmacol., 40, 53-54 (1987).
4. M. Mezei, Can. Pharm. J., 124, 132-155 (1991).
5. T. Ogiso, N. Niinaka, and M. Iwaki, J. Pharm. Sci., 85, 57-64 (1996).
6. M. Mezei, in Drug Permeation Enhancement: Theory and Applications (D. S. Hsieh, Eds.), DNLM, New York, 1994, pp. 171-198.
7. J. Lasch and W. Wohlrab, Biomed. Biochim. Acta, 45, 1295-1299 (1986).
8. H. Benameur, G. Grand, and R. Brasseur, Int. J. Pharm., 89, 157-167 (1993).
9. M. Mihalic', H. Hofman, and J. Kuftinec, Analytical Profiles Drug Substances, Academic, San Diego, 1986, pp. 509-531.
10. A. Babar, A. J. C. Solanki, and F. Plakogiannis, Drug Dev. Ind. Pharm., 16, 523-540 (1990).
11. D. L. Larson and J. G. Lombardino, Agents Actions, 10, 246-251 (1980).
12. T. Kageyama, Eur. J. Rheumatol. Inflamm., 8, 114-115 (1987).
13. N. Weiner, F. Martin, and M. Riaz, Drug Dev. Ind. Pharm., 15, 1523-1554 (1989).
14. E. E. Linn, R. C. Pohland, and T. K. Byrd, Drug Dev. Ind. Pharm., 16, 899-920 (1990).
15. N. A. Monteiro-Riviere, A. O. Imman, and J. E. Riviere, Pharm. Res., 10, 1326-1331 (1993).
16. R. Marks and P. Dykes, Skin Pharmacol., 7, 340-344 (1994).
17. D. Lasic, Am. Sci., 80, 20-31 (1992).
18. A. D. Bangham and R. W. Home, J. Mol. Biol., 8, 660-668 (1964).
19. A. D. Bangham, M. M. Standish, and J. C. Watkins, J. Mol. Biol., 13, 238-252 (1965).
20. R. R. C. New, in Liposomes: a Practical Approach (R. R. C. New, Ed.), IRL Press, Oxford, England, 1990, pp. 33-104.
21. D. W. Fry, C. White, and D. Goldman, J. Anal. Biochem., 90, 809 (1978).
22. R. R. C. New, in Liposomes: a Practical Approach (R. R. C. New, Ed.), IRL Press, Oxford, England, 1990, pp. 105-161.
23. C. J. E. Niemegeers, W. V. Bruggen, and F. Awouters, Arzneim.-Forsch., 25, 1524-1526 (1975).
24. D. H. P. Germano, T. T. O. Caldeira, and A. A. A. Mazella, Fitoterapia, 54, 459-462 (1993).
25. N. Weiner and L. Lieb, in Medical Application of Liposomes (D. D. Lasic and D. Papahadjoupoulos, Eds.), Elsevier, New York, 1998, pp. 493-513.
26. I. R. Fornovi, M. T. G. Ramón, and A. M. Rivera, Afinidad, 46, 460-466 (1989).
27. B.W. Barry, in Pharmaceutical Dosage Forms: Disperse Systems, Vol. I (H. A. Lieherman, M. M. Rieger, and G. S. Banker, Eds.), DNLM, New York, 1988, pp. 245-283.
28. R. Viglioglia, Cosmiatria II, AP Americana, Buenos Aires, 1991, pp. 105-107.
29. E. Touitou, N. Shaco-Ezra, and N. Dayan, J. Pharm. Sci., 81, 131-134 (1992).
30. E. Fattal and F. Puisieux, in Formes Pharmaceutiques pour application locale (M. Seiller and M. C. Martini, Eds.), Tec and Doc Lavoisier, Paris, 1996, pp. 396-411.
31. V. Masini, F. Bonte, and A. Meybeck, J. Pharm. Sci., 82, 17-21 (1993).
32. H. E. Holland, J. A. Bouwstra, H. E. Bodde, F. Spies, and H. E. Junginger, Br. J. Dermatol., 132, 853-866 (1995).